AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10089860 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacing after cardiac transplantation
Number of subjects: 0
Study 10089860 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacing for hemodynamic improvement in first-degree atrioventricular block
Number of subjects: 0
Study 8942493 — intervention group
Group type: EXPERIMENTAL
Intervention: GYNE-T 380
Number of subjects: 592
Study 8942493 — intervention group
Group type: COMPARATOR
Intervention: GYNE-T 380 Postpartum
Number of subjects: 592
Study 1749710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-prepared product containing 0.5% dithranol
Number of subjects: 35
Study 1749710 — intervention group
Group type: COMPARATOR
Intervention: Commercial product containing 0.5% dithranol
Number of subjects: 35
Study 28853328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 31
Study 30900083 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative Practices Intervention
Number of subjects: 2771
Study 30900083 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 2771
Study 28849269 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation (RMN)
Number of subjects: 218
Study 28849269 — intervention group
Group type: COMPARATOR
Intervention: Manual approach
Number of subjects: 218
Study 25736101 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with remifentanil
Number of subjects: 100
Study 25736101 — intervention group
Group type: COMPARATOR
Intervention: Desflurane with remifentanil
Number of subjects: 100
Study 25736101 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 23869940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study 23869940 — intervention group
Group type: COMPARATOR
Intervention: Control (Vitamin D sterols and phosphate binders alone)
Number of subjects: 0
Study 22321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy selective laser trabeculoplasty (SLT) using half of conventional laser energy and 100 spots over 360° of the trabecular meshwork.
Number of subjects: 74
Study 22321497 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser energy (control group).
Number of subjects: 74
Study 22321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy selective laser trabeculoplasty (SLT) in POAG.
Number of subjects: 74
Study 22321497 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser energy (control group) in POAG.
Number of subjects: 74
Study 22321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications from low-energy SLT.
Number of subjects: 74
Study 22321497 — intervention group
Group type: COMPARATOR
Intervention: Complications from conventional laser energy.
Number of subjects: 74
Study 22321497 — intervention group
Group type: COMPARATOR
Intervention: Transient IOP spike (≥ 3 mm Hg) in control group.
Number of subjects: 74
Study 22321497 — intervention group
Group type: COMPARATOR
Intervention: Partial peripheral anterior synechiae in control group.
Number of subjects: 74
Study 19671259 — intervention group
Group type: EXPERIMENTAL
Intervention: Postirradiated NPC patients with CNS infection
Number of subjects: 18
Study 19671259 — intervention group
Group type: COMPARATOR
Intervention: NPC patients without CNS infection (control group)
Number of subjects: 18
Study 17557984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg + LCD (one meal-replacement shake; two low-calorie meals; total kcal/d approximately 1200-1500)
Number of subjects: 148
Study 17557984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg + LCD
Number of subjects: 148
Study 17557984 — intervention group
Group type: COMPARATOR
Intervention: Placebo + three low-calorie meals (total kcal/d approximately 1200-1500)
Number of subjects: 148
Study 17557984 — intervention group
Group type: COMPARATOR
Intervention: Placebo + three low-calorie meals
Number of subjects: 148
Study 15572994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercises for 1 hour twice weekly for 12 weeks
Number of subjects: 18
Study 15572994 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy exercises focused on improvement of balance for 1 hour twice weekly for 12 weeks
Number of subjects: 18
Study 11507354 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 350
Study 11507354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily plus cisapride 20 mg twice daily
Number of subjects: 350
Study 11507354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 350
Study 9631925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine (CsA) administered twice daily
Number of subjects: 69
Study 9631925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine (CsA) with concomitant diltiazem administration
Number of subjects: 69
Study 9631925 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive performance assessment in a reserved subset of 33 patients
Number of subjects: 69
Study 9631925 — intervention group
Group type: EXPERIMENTAL
Intervention: Population modeling using NONMEM
Number of subjects: 69
Study 7517238 — intervention group
Group type: EXPERIMENTAL
Intervention: H1/H2 receptor blockers (1 mg/kg ranitidine and 0.1 mg/kg dimetinden) administered 15 min before protamine administration
Number of subjects: 20
Study 7517238 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control group)
Number of subjects: 20
Study 2525044 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 0
Study 2525044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 0
Study 2525044 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium and Suxamethonium
Number of subjects: 0
Study 4914614 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyprylon (300 mg)
Number of subjects: 50
Study 4914614 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutethimide (500 mg)
Number of subjects: 50
Study 4914614 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (1000 mg)
Number of subjects: 50
Study 31287963 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise intervention with daily HRV monitoring
Number of subjects: 55
Study 31287963 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderation of exercise volume in response to HRV shifts
Number of subjects: 55
Study 30520964 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery (laparoscopic salpingotomy)
Number of subjects: 0
Study 30520964 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (Methotrexate)
Number of subjects: 0
Study 28167180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group (PG)
Number of subjects: 30
Study 28167180 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 26517847 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate screening
Number of subjects: 851535
Study 26517847 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponed screening
Number of subjects: 851535
Study 26517847 — intervention group
Group type: COMPARATOR
Intervention: Never invited
Number of subjects: 851535
Study 23291565 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact unilateral exercise intervention (50 multidirectional hops, 7 days a week on one leg)
Number of subjects: 50
Study 23291565 — intervention group
Group type: COMPARATOR
Intervention: Control leg (no exercise)
Number of subjects: 50
Study 23291565 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact unilateral exercise intervention
Number of subjects: 50
Study 20974593 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D₂ (PGD₂) infusion at 384 ng/kg/min over 25 min
Number of subjects: 12
Study 20974593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20974593 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D₂ (PGD₂) infusion
Number of subjects: 12
Study 18647212 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural change techniques
Number of subjects: 17
Study 18647212 — intervention group
Group type: COMPARATOR
Intervention: Standard care treatment (dietitians with no formal training in behavioural change techniques)
Number of subjects: 17
Study 16234224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (4 capsules taken one hour before sexual activity for 2 weeks)
Number of subjects: 10
Study 16234224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 identical capsules for 2 weeks)
Number of subjects: 10
Study 15127994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bovine hydroxyapatite (Bio‐Oss) and autogenous bone chips stabilized with Tisseel
Number of subjects: 30
Study 10736385 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium L-glutamate (MSG) 1.5 g/person
Number of subjects: 52
Study 10736385 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium L-glutamate (MSG) 3.0 g/person
Number of subjects: 52
Study 10736385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8615394 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg orally thrice daily for 12 days
Number of subjects: 18
Study 8615394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1394753 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal injection of 1.0 ml.kg-1 bupivacaine 0.125% with epinephrine 1:400,000 and fentanyl 1.0 microgram.kg-1 in 1.0 ml of normal saline
Number of subjects: 34
Study 1394753 — intervention group
Group type: COMPARATOR
Intervention: Caudal injection of 1.0 ml.kg-1 bupivacaine 0.125% with epinephrine 1:400,000 and normal saline
Number of subjects: 34
Study 4059300 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.03 mg/kg)
Number of subjects: 93
Study 4059300 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (5 mg/kg) plus gallamine (0.3 mg/kg)
Number of subjects: 93
Study 4059300 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (5 mg/kg)
Number of subjects: 93
Study 31174579 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based virtual reality training (VRT) for standing balance, stepping, reaching, strengthening, and gentle aerobic fitness, performed for 30 minutes, 5 days a week for 6 weeks.
Number of subjects: 40
Study 31174579 — intervention group
Group type: COMPARATOR
Intervention: iPad with apps selected to rehabilitate cognition, hand fine motor skills, and visual tracking/scanning, performed for 30 minutes, 5 days a week for 6 weeks.
Number of subjects: 40
Study 31174579 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VRT and control) will be assessed for standing balance, gait, and community integration.
Number of subjects: 40
Study 29034524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dopamine infusion (3 μg kg-1 min-1)
Number of subjects: 9
Study 29034524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 9
Study 26777066 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERACT quality improvement program
Number of subjects: 64
Study 24835247 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccine (MV)
Number of subjects: 0
Study 23224924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-citrulline supplementation (3 g/day)
Number of subjects: 35
Study 23224924 — intervention group
Group type: COMPARATOR
Intervention: Control group (without supplementation)
Number of subjects: 35
Study 20927359 — intervention group
Group type: EXPERIMENTAL
Intervention: IET + AC (intervention group, n=246)
Number of subjects: 496
Study 20927359 — intervention group
Group type: COMPARATOR
Intervention: Nasal suction (NS, control group, n=250)
Number of subjects: 496
Study 20927359 — intervention group
Group type: EXPERIMENTAL
Intervention: IET + AC (intervention group)
Number of subjects: 496
Study 17986309 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fulvestrant 70 mg mL(‐1) solution
Number of subjects: 172
Study 17986309 — intervention group
Group type: COMPARATOR
Intervention: Minoxidil 2% solution
Number of subjects: 172
Study 17986309 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 172
Study 15824848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neridronate (2 mg/kg infused IV in 30 minutes every 3 months)
Number of subjects: 64
Study 15824848 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment for the first year)
Number of subjects: 64
Study 15824848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neridronate
Number of subjects: 64
Study 11809521 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of caffeine
Number of subjects: 20
Study 11809521 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 20
Study 11809521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9708651 — intervention group
Group type: EXPERIMENTAL
Intervention: Early primary ventricular fibrillation (VF)
Number of subjects: 9720
Study 9708651 — intervention group
Group type: EXPERIMENTAL
Intervention: Late primary ventricular fibrillation (VF)
Number of subjects: 9720
Study 9708651 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (no primary VF)
Number of subjects: 9720
Study 7636529 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule 1: Etoposide 130 mg/m2/d IV for 3 days and cisplatin 25 mg/m2/d IV for 3 days every 21 days for eight courses.
Number of subjects: 306
Study 7636529 — intervention group
Group type: COMPARATOR
Intervention: Schedule 2: Etoposide 50 mg/m2/d orally for 21 days and cisplatin 33 mg/m2/d IV for 3 days every 28 days for six courses.
Number of subjects: 306
Study 1964470 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody BW 494
Number of subjects: 150
Study 638442 — intervention group
Group type: EXPERIMENTAL
Intervention: isotonic sodium chloride
Number of subjects: 12
Study 638442 — intervention group
Group type: COMPARATOR
Intervention: 5 per cent glucose in water
Number of subjects: 12
Study 30958962 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led dental education (PLDE)
Number of subjects: 0
Study 30958962 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental instruction (CDI)
Number of subjects: 0
Study 29438120 — intervention group
Group type: EXPERIMENTAL
Intervention: MiSight contact lenses (CLs)
Number of subjects: 74
Study 29438120 — intervention group
Group type: COMPARATOR
Intervention: Distance single-vision (SV) spectacles
Number of subjects: 74
Study 26869609 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 kcal/d
Number of subjects: 36
Study 26869609 — intervention group
Group type: COMPARATOR
Intervention: 500 kcal/d
Number of subjects: 36
Study 24884684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant application (experimental group - n=17)
Number of subjects: 36
Study 24884684 — intervention group
Group type: COMPARATOR
Intervention: Restoration with composite resin (control group - n=19)
Number of subjects: 36
Study 22896584 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ICD
Number of subjects: 229
Study 19839966 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release dexamphetamine (up to 110 mg/day)
Number of subjects: 49
Study 19839966 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study 17653683 — intervention group
Group type: EXPERIMENTAL
Intervention: Style 410 implants (MG)
Number of subjects: 80
Study 17653683 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertex implants (ES)
Number of subjects: 80
Study 17653683 — intervention group
Group type: COMPARATOR
Intervention: Both implants (MG and ES)
Number of subjects: 80
Study 16287669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice plus pulsed electromagnetic field (group A)
Number of subjects: 83
Study 16287669 — intervention group
Group type: COMPARATOR
Intervention: Ice plus sham pulsed electromagnetic field (group B)
Number of subjects: 83
Study 16287669 — intervention group
Group type: COMPARATOR
Intervention: Pulsed electromagnetic field alone (group C)
Number of subjects: 83
Study 16287669 — intervention group
Group type: COMPARATOR
Intervention: Sham pulsed electromagnetic field treatment (group D)
Number of subjects: 83
Study 12039025 — intervention group
Group type: EXPERIMENTAL
Intervention: CT fluoroscopy
Number of subjects: 20
Study 10546860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens of two nucleoside analogues
Number of subjects: 10000
Study 10546860 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine combined with either didanosine or zalcitabine
Number of subjects: 10000
Study 10546860 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple regimen including a protease inhibitor
Number of subjects: 10000
Study 10546860 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 10000
Study 7721576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin applied to the frontotemporal region (5 mg in 2% ointment for 2 hours)
Number of subjects: 100
Study 7721576 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin applied to the neck, arm, and forearm regions (5 mg in 2% ointment for 2 hours)
Number of subjects: 100
Study 2044338 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial family interview (I)
Number of subjects: 177
Study 2044338 — intervention group
Group type: COMPARATOR
Intervention: Non-interviewed (NI)
Number of subjects: 177
Study 7304900 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia (modified technique with reduced bupivacaine concentration)
Number of subjects: 611
Study 7304900 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia
Number of subjects: 611
Study 7304900 — intervention group
Group type: COMPARATOR
Intervention: No extradural analgesia
Number of subjects: 611
Study 31416453 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised guideline support tool
Number of subjects: 168
Study 31416453 — intervention group
Group type: COMPARATOR
Intervention: Paper-based guideline (control)
Number of subjects: 168
Study 26406600 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendex
Number of subjects: 0
Study 26406600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovis
Number of subjects: 0
Study 25023094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment (10 sessions)
Number of subjects: 54
Study 25023094 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound (10 sessions)
Number of subjects: 54
Study 22172923 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency low-intensity electrotherapy
Number of subjects: 36
Study 22172923 — intervention group
Group type: COMPARATOR
Intervention: Manual lymphatic drainage
Number of subjects: 36
Study 20587587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment (target glycated hemoglobin level <6.0%)
Number of subjects: 10251
Study 20587587 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for glycemia (target glycated hemoglobin level 7.0 to 7.9%)
Number of subjects: 10251
Study 20587587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate for intensive dyslipidemia therapy (160 mg daily plus simvastatin)
Number of subjects: 10251
Study 20587587 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus simvastatin for dyslipidemia
Number of subjects: 10251
Study 20587587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood-pressure therapy (target systolic blood pressure <120 mm Hg)
Number of subjects: 10251
Study 20587587 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for blood-pressure control (target systolic blood pressure <140 mm Hg)
Number of subjects: 10251
Study 17386166 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus PMR (PMR)
Number of subjects: 30
Study 17386166 — intervention group
Group type: COMPARATOR
Intervention: Medication group (M)
Number of subjects: 30
Study 17386166 — intervention group
Group type: EXPERIMENTAL
Intervention: PMR
Number of subjects: 30
Study 16241873 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless two-way pager-based automated messaging system
Number of subjects: 0
Study 16241873 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12197851 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 2367
Study 12197851 — intervention group
Group type: COMPARATOR
Intervention: TCAs
Number of subjects: 2367
Study 10444123 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP (transurethral resection using a standard cutting-wire loop)
Number of subjects: 0
Study 10444123 — intervention group
Group type: COMPARATOR
Intervention: TUEVAP (transurethral electrovaporization using a modified roller electrode)
Number of subjects: 0
Study 10444123 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 0
Study 10444123 — intervention group
Group type: COMPARATOR
Intervention: TUEVAP
Number of subjects: 0
Study 7802296 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (300 micrograms/kg/min during CPB after a bolus of 2 mg/kg prior to CPB)
Number of subjects: 30
Study 7802296 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30
Study 7802296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2107762 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate monotherapy
Number of subjects: 55
Study 2107762 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate combination therapy
Number of subjects: 55
Study 2107762 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 55
Study 6756508 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 88
Study 6756508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus CMF chemotherapy
Number of subjects: 88
Study 31226144 — intervention group
Group type: EXPERIMENTAL
Intervention: Night alarm mobilisation
Number of subjects: 16
Study 31226144 — intervention group
Group type: EXPERIMENTAL
Intervention: Day alarm mobilisation
Number of subjects: 16
Study 31226144 — intervention group
Group type: COMPARATOR
Intervention: Night control (gentle awakening)
Number of subjects: 16
Study 31226144 — intervention group
Group type: COMPARATOR
Intervention: Day control
Number of subjects: 16
Study 28572068 — intervention group
Group type: EXPERIMENTAL
Intervention: TV cooking show without portion-size cue
Number of subjects: 0
Study 28572068 — intervention group
Group type: EXPERIMENTAL
Intervention: TV cooking show with portion-size cue
Number of subjects: 0